Amgen, a prominent player in manufacturing and delivering innovative medicines announced a USD 650 Million expansion of its U.S. manufacturing network, creating hundreds of new jobs.
This step will support increased pharmaceutical manufacturing at the biologics facility of the company in Juncos and integrate innovative advanced technologies throughout the operations process. It is projected to create nearly 750 jobs, including construction roles and new highly skilled manufacturing jobs.
The company’s long-standing commitment to U.S. innovation as well as state-of-the-art services is reflected in more than USD 40 billion invested in manufacturing and research and development since the passage of the Tax Cuts and Jobs Act (TCJA) of 2017. The enactment of pro-growth tax policies in TCJA, extended and reinforced by the One Big Beautiful Bill Act of 2025, further facilitates Amgen's ability to invest domestically in cutting-edge science and manufacturing.
The startegic step builds on Amgen's recent investments, including a USD 600 million science and innovation center in California and manufacturing expansions of USD 900 million in Ohio and USD 1 billion in North Carolina, respectively.
Executive Statement
According to Robert A. Bradway, chairman and chief executive officer at Amgen, this expansion underscores Amgen's commitment to U.S. biomanufacturing and to strengthening the resilience of our global supply chain. By growing their capacity to deliver innovative medicines with cutting edge technology in their manufacturing plants, they will not only better serve patients but also create high-quality jobs that reinforce America's leadership in biotechnology.
